Meta-Analysis:
Metaanalysis of the incidence and risks of interstitial lung disease and QTc prolongation in nonsmallcell lung cancer patients treated with ALK inhibitors
PDF | Full Text | How to cite
Metrics: PDF 2421 views | Full Text 2788 views
Liping Lin1,4,*, Juanjuan Zhao2,*, Ning Kong3,4, Yan He1,4, Jiazhu Hu1,4, Fuxi Huang1,4, Jianjun Han1,4 and Xiaolong Cao1,4
1Department of Oncology, Panyu Central Hospital, Guangzhou, 511400, China
2School of Nursing, Sun Yat-sen University, Guangzhou, 510000, China
3Department of Ophthalmology, Panyu Central Hospital, Guangzhou, 511400, China
4Cancer Institute of Panyu, Guangzhou, 511400, China
*These authors contributed equally to this work
Correspondence to:
Liping Lin, email: [email protected]
Keywords: ALK-TKIs, interstitial lung disease, QTc prolongation, non-small-cell lung cancer, meta-analysis
Received: April 16, 2017 Accepted: May 03, 2017 Published: May 29, 2017
ABSTRACT
Background: To conduct a systematic review and meta-analysis to assess the overall incidence and risk of interstitial lung disease (ILD) and QTc prolongation associated with anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors (-TKIs) in non-small-cell lung cancer (NSCLC) patients.
Results: A total of 1,770 patients from 8 clinical trials were included. The incidences of high-grade ILD and QTc prolongation was 2.5% (95% CI 1.7-3.6%), and 2.8% (95% CI 1.8-4.3%), respectively. Meta-analysis demonstrated that the use of ALK-TKIs in NSCLC patients significantly increased the risk of developing high-grade ILD (Peto OR, 3.27, 95%CI: 1.18–9.08, p = 0.023) and QTc prolongation (Peto OR 7.51, 95% CI, 2.16–26.15; p = 0.002) in comparison with chemotherapy alone.
Materials and Methods: A systematic literature search was performed to identify related citations up to January 31, 2017. Data were extracted, and summary incidence rates, Peto odds ratios (Peto ORs), and 95% confidence intervals (CIs) were calculated.
Conclusions: The use of ALK-TKIs significantly increases the risk of developing high-grade ILD and QTc prolongation in lung cancer patients. Clinicians should pay attention to the risks of severe ILD and QTc prolongation with the administration of these drugs.